Belimumab in refractory systemic lupus erythematosus pleural effusion

Med Clin (Barc). 2022 Jan 7;158(1):42-43. doi: 10.1016/j.medcli.2020.12.036. Epub 2021 Mar 23.

[Article in English, Spanish]

Authors

Vicenç Torrente-Segarra¹, Maria Bonet²

Affiliations

¹ Rheumatology Department; Hospital Comarcal Alt Penedès-Garraf (CSAPG), Vilafranca del Penedès, Spain. Electronic address: [email protected].
² Rheumatology Department; Hospital Comarcal Alt Penedès-Garraf (CSAPG), Vilafranca del Penedès, Spain.

PMID: 33771364
DOI: 10.1016/j.medcli.2020.12.036

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Humans
Immunosuppressive Agents / therapeutic use
Lupus Erythematosus, Systemic* / complications
Lupus Erythematosus, Systemic* / drug therapy
Pleural Effusion* / drug therapy
Pleural Effusion* / etiology
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Immunosuppressive Agents
belimumab